Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wildes

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Protein Science : a Publication of the Protein Society|December 4, 2004
Hydrogen exchange and ligand binding: ligand-dependent and ligand-independent protection in the Src SH3 domainDavid Wildes, Susan Marqusee
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2010
Sampling the N-terminal proteome of human bloodDavid Wildes, James A Wells
Protein Science : a Publication of the Protein Society|June 6, 2006
Native state energetics of the Src SH2 domain: evidence for a partially structured state in the denatured ensembleDavid Wildes, L Meadow Anderson, Alex Sabogal, et al.
Protein Science : a Publication of the Protein Society|February 28, 2006
On the precision of experimentally determined protein folding rates and phi-valuesMiguel A de los Rios, B K Muralidhara, David Wildes, et al.
Frontiers in Oncology|August 19, 2021
Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic LeukemiaBianca J Lee, Sharmila Mallya, Nuntana Dinglasan, et al.
Cancer Research|May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive EnvironmentElsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Frontiers in Immunology|November 2, 2020
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor ImmunityDarienne R Myers, Clare L Abram, David Wildes, et al.
Nature Communications|July 18, 2024
Combined inhibition of KRAS<sup>G12C</sup> and mTORC1 kinase is synergistic in non-small cell lung cancerHidenori Kitai, Philip H Choi, Yu C Yang, et al.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
Nature Cell Biology|August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancersRobert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Protein Science : a Publication of the Protein Society|December 4, 2004
Hydrogen exchange and ligand binding: ligand-dependent and ligand-independent protection in the Src SH3 domainDavid Wildes, Susan Marqusee
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2010
Sampling the N-terminal proteome of human bloodDavid Wildes, James A Wells
Protein Science : a Publication of the Protein Society|June 6, 2006
Native state energetics of the Src SH2 domain: evidence for a partially structured state in the denatured ensembleDavid Wildes, L Meadow Anderson, Alex Sabogal, et al.
Protein Science : a Publication of the Protein Society|February 28, 2006
On the precision of experimentally determined protein folding rates and phi-valuesMiguel A de los Rios, B K Muralidhara, David Wildes, et al.
Frontiers in Oncology|August 19, 2021
Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic LeukemiaBianca J Lee, Sharmila Mallya, Nuntana Dinglasan, et al.
Cancer Research|May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive EnvironmentElsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Frontiers in Immunology|November 2, 2020
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor ImmunityDarienne R Myers, Clare L Abram, David Wildes, et al.
Nature Communications|July 18, 2024
Combined inhibition of KRAS<sup>G12C</sup> and mTORC1 kinase is synergistic in non-small cell lung cancerHidenori Kitai, Philip H Choi, Yu C Yang, et al.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
Nature Cell Biology|August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancersRobert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Pageof 3